← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $614B	2,933	-59	-2%	$240B
2	2 Merck MRK $362B	2,477	-61	-2%	$147B
3	3 Pfizer PFE $169B	2,437	-89	-4%	$130B
4	4 AbbVie ABBV $504B	2,225	-19	-0.8%	$82.6B
5	5 Bristol-Myers Squibb BMY $124B	2,148	-71	-3%	$95.4B
6	6 Amgen AMGN $235B	2,028	-80	-4%	$91.7B
7	7 Gilead Sciences GILD $194B	1,642	+85	+5%	$74.9B
8	8 Novartis NVS $287B	1,132	-41	-3%	$20.4B
9	9 GSK GSK $99.3B	817	-78	-9%	$11.9B
10	10 Regeneron Pharmaceuticals REGN $81.8B	816	+113	+16%	$36.9B
11	11 AstraZeneca AZN $256B	604	-31	-5%	$19.8B
12	12 Incyte INCY $22.8B	490	-66	-12%	$14.7B
13	13 DELISTED Exact Sciences EXAS	475	-52	-10%	$7.66B
14	14 Jazz Pharmaceuticals JAZZ $13.6B	407	-39	-9%	$5B
15	SGEN 15 DELISTED Seagen Inc. Common Stock SGEN	392	-4	-1%	$19B
16	16 Exelixis EXEL $15.4B	337	+8	+2%	$4.25B
17	17 Takeda Pharmaceutical TAK $62.7B	313	-26	-8%	$1.76B
18	18 Guardant Health GH $21.5B	288	+20	+7%	$5.46B
19	19 NeoGenomics NEO $2.14B	272	+11	+4%	$2.61B
20	20 Qiagen QGEN $9.53B	260	-37	-12%	$5.98B
21	21 Iovance Biotherapeutics IOVA $6.17B	219	+19	+10%	$3.67B
22	22 BeOne Medicines Ltd ONC $41.8B	215	-6	-3%	$6.05B
23	23 DELISTED Blueprint Medicines BPMC	214	-14	-6%	$3.2B
24	24 Halozyme HALO $13.8B	210	-14	-6%	$2.36B
25	25 Natera NTRA $56.5B	191	-10	-5%	$2.23B